Xeris Biopharma Holdings, Inc. reported $335M of revenue over the trailing twelve months, +36% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $335M (to Q2 2026). Net income: −$17M, trailing twelve months to Q2 2026. Operating margin: 11%, trailing twelve months to Q2 2026. EPS: −$0.10, trailing twelve months to Q2 2026.

XERSXeris Biopharma Holdings, Inc.

Healthcare

$10.48+36% 1Y

$10.48

$5.2952 weeks$10.48

Latest close: a new 52-week highOct 9, 2026what changed →

XERS as reported

Xeris Biopharma Holdings, Inc. reported $335M of revenue over the trailing twelve months, +36% on the year before. 9 reported series are charted on this page, each one as filed.

$335M

Revenue, trailing twelve months · to Q2 2026 · +36% against the twelve months before

Net income: −$17M
Net income · −46% year on year · trailing twelve months to Q2 2026
Operating margin: 11%
Operating margin · trailing twelve months to Q2 2026
EPS: −$0.10
EPS · −52% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for XERS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$335M	+36%	Q2 2026
Net income	−$17M	−46%	Q2 2026
EPS	−$0.10	−52%	Q2 2026
Gross margin	87%	n/a	Q2 2026
Operating margin	11%	n/a	Q2 2026
Net margin	−4.3%	n/a	Q2 2026
ROE	522%	n/a	Q2 2026
ROA	−1.3%	n/a	Q2 2026
ROIC	17%	n/a	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.